Health care stocks were advancing premarket Friday as the Health Care Select Sector SPDR Fund (XLV) was up 0.5% and the iShares Biotechnology ETF (IBB) was 0.6% higher recently.
Novo Nordisk's (NVO) obesity and diabetes drug semaglutide has a "very rare side effect" whereby patients taking the drug could develop a condition that may cause loss of vision, the European Medicines Agency said. Novo Nordisk shares were more than 2% higher pre-bell.
Arvinas (ARVN) and Pfizer (PFE) submitted a new drug application to the US Food and Drug Administration for vepdegestrant as a treatment for patients with ESR1-mutated advanced or metastatic breast cancer. Arvinas shares were up more than 1% premarket.
BioCryst Pharmaceuticals (BCRX) shares were 0.7% higher after the company said its Orladeyo drug has been approved for reimbursement in the Netherlands for the routine prevention of hereditary angioedema attacks in patients aged 12 years and up.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。